Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency

• Published in: European heart journal. Quality of care & clinical outcomes 2023-02, Vol.9 (2), p.109-118
• Main Authors: Szymański, Piotr, Weidinger, Franz, Lordereau-Richard, Isabelle, Himmelmann, Anders, Arca, Marcello, Chaves, Jose, Lee, Charles, Jonker, Carla, Kotecha, Dipak, O'Kelly, James, Plueschke, Kelly, Ryś, Andrzej, Segec, Andrej, Wallentin, Lars, Veltrop, Rogier, James, Stefan
• Format: Article
• Language: English
• Subjects: Cardiology; Clinical trials; DARWIN EU; Electronic healthcare records; EuroHeart; Fit-for-purpose registries; Humans; Registries; Registry-based randomised clinical trials
• ISSN: 2058-5225; 2058-1742; 2058-1742
• DOI: 10.1093/ehjqcco/qcad009

Abstract Real world data (RWD) refers to healthcare information that is routinely collected in electronic healthcare records (EHR), hospital and pharmacy records, patient and disease registries, and health insurance databases. The collection and analysis of this vast amount of data is an important complement to that obtained from conventional randomised controlled trials (RCT). Real world data has been used for healthcare quality improvements, to conduct clinical trials, to support drug and device development, and to inform medical guidelines. The utility of RWD may be facilitated by common data models, which standardise format and content, and allow data from different health systems to be analysed together. The European Society of Cardiology (ESC) supports the use of RWD in collaboration with national cardiac societies, regulatory authorities, and industry to encourage continuous quality of care improvements at the hospital and country level, to conduct registry-based randomised clinical trials (R-RCT) and to facilitate safety surveillance of novel drugs and devices. The European Medicines Agency (EMA) is developing systems and processes to enable the use of RWD that can help in trial planning, defining clinical contexts, and enhancing outcome assessments. RWD can also contribute to the measurement of the impact of regulatory actions, such as contraindications or restriction of indications by looking at medicines use patterns over time across European Member States. A number of other initiatives from the European Commission and the EMA are underway to strengthen the EU's health security framework, and foster the collection and utilisation of RWD. Graphical Abstract Graphical Abstract Examples of types of data that can be collected as part of routine care.